Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models

Oncotarget

Volumn 6, Issue 21, 2015, Pages 18545-18557

  D'Aronzo, Martina ^a   Vinciguerra, Manlio ^a,b,c   Mazza, Tommaso ^d   Panebianco, Concetta ^a   Saracino, Chiara ^a   Pereira, Stephen P ^b   Graziano, Paolo ^a   Pazienza, Valerio ^a  

^a Gastroenterology Unit IRCCS Casa Sollievo della Sofferenza Hospital San Giovanni Rotondo (FG) Italy   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Gemcitabine; hENT1; Pancreatic cancer

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; GEMCITABINE; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CULTURE MEDIUM; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; RRM1 PROTEIN, HUMAN; SLC29A1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DIET RESTRICTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BOVINE; CELL CYCLE; CELL MOTION; CELL SURVIVAL; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; DRUG SCREENING; FETUS BLOOD; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOBLOTTING; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PHARMACOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CATTLE; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CULTURE MEDIA; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FASTING; FEMALE; FETAL BLOOD; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938797129     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4186     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225-249.
2. Hariharan D, Saied A and Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008; 10:58-62.
3. Warshaw AL and Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992; 326:455-465.
4. Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer. 2002; 95:941-945.
5. Rathos MJ, Joshi K, Khanwalkar H, Manohar SM and Joshi KS. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. J Transl Med. 2012; 10:161.
6. Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y and Miyagi Y. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol. 2012; 19 Suppl 3:S558-564.
7. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP and Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009; 136:187-195.
8. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 2003; 9:5000-5008.
9. Jordheim LP, Seve P, Tredan O and Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 2011; 12:693-702.
10. Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y and Bepler G. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 2009; 28:2903-2909.
11. Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X and Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 2013; 119:173-181.
12. Lee C and Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011; 30:3305-3316.
13. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, Emionite L, de Cabo R and Longo VD. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012; 4:124ra127.
14. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G and Longo VD. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A. 2008; 105:8215-8220.
15. Quint K, Tonigold M, Di Fazio P, Montalbano R, Lingelbach S, Ruckert F, Alinger B, Ocker M and Neureiter D. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int J Oncol. 2012; 41:2093-2102.
16. Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, Banzato F, D'Incalci M and Ubezio P. Cell cycle effects of gemcitabine. Int J Cancer. 2001; 93:401-408.
17. Han L, Ma Q, Li J, Liu H, Li W, Ma G, Xu Q, Zhou S and Wu E. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One. 2011; 6:e27074.
18. Pandolfi A and Di Pietro N. High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycaemia? Cardiovasc Res. 2010; 86:9-11.
19. Perez-Torras S, Garcia-Manteiga J, Mercade E, Casado FJ, Carbo N, Pastor-Anglada M and Mazo A. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol. 2008; 76:322-329.
20. Puebla C, Farias M, Gonzalez M, Vecchiola A, Aguayo C, Krause B, Pastor-Anglada M, Casanello P and Sobrevia L. High D-glucose reduces SLC29A1 promoter activity and adenosine transport involving specific protein 1 in human umbilical vein endothelium. J Cell Physiol. 2008; 215:645-656.
21. Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G and Graziano F. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol. 2010; 223:384-388.
22. Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst. 2014; 106:djt347.
23. Tavano F, Fontana A, Pellegrini F, Burbaci FP, Rappa F, Cappello F, Copetti M, Maiello E, Lombardi L, Graziano P, Vinciguerra M, di Mola FF, di Sebastiano P, Andriulli A and Pazienza V. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. J Transl Med. 2014; 12:248.
24. Zhu Y, Qi M, Lao L, Wang W, Hua L and Bai G. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Genet Test Mol Biomarkers. 2014; 18:306-312.
25. Apontes P, Leontieva OV, Demidenko ZN, Li F and Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2:222-233.
26. Longo VD and Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging (Albany NY). 2011; 3:1039-1040.
27. Guillaumond F, Iovanna JL and Vasseur S. Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways. Arch Biochem Biophys. 2014; 545:69-73.
28. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014; 124:1525-1536.
29. Li D, Xie K, Wolff R and Abbruzzese JL. Pancreatic cancer. Lancet. 2004; 363:1049-1057.
30. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324:1457-1461.
31. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM and Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut. 2011; 60:861-868.
32. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD and Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21:418-429.
33. Longo VD and Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014; 19:181-192.
34. Brandhorst S, Wei M, Hwang S, Morgan TE and Longo VD. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol. 2013; 48:1120-1128.
35. Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R and Pili R. Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget. 2013; 4:2451-2461.
36. Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L and Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010; 9:4474-4476.
37. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P and Longo VD. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009; 1:988-1007.
38. Matsubara S, Ding Q, Miyazaki Y, Kuwahata T, Tsukasa K and Takao S. mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. Sci Rep. 2013; 3:3230.
39. Kagawa S, Takano S, Yoshitomi H, Kimura F, Satoh M, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Furukawa K, Matsushita K, Nomura F and Miyazaki M. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res. 2012; 178:758-767.
40. Harvey AE, Lashinger LM, Hays D, Harrison LM, Lewis K, Fischer SM and Hursting SD. Calorie restriction decreases murine and human pancreatic tumor cell growth, nuclear factor-kappaB activation, and inflammation-related gene expression in an insulin-like growth factor-1-dependent manner. PLoS One. 2014; 9:e94151.
41. Mathews EH and Liebenberg L. Short-term starvation for cancer control in humans. Exp Gerontol. 2013; 48(11):1293.
42. Pazienza V, Borghesan M, Mazza T, Sheedfar F, Panebianco C, Williams R, Mazzoccoli G, Andriulli A, Nakanishi T and Vinciguerra M. SIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against lipid accumulation. Aging (Albany NY). 2014; 6:35-47.
43. Benegiamo G, Vinciguerra M, Mazzoccoli G, Piepoli A, Andriulli A and Pazienza V. DNA methyltransferases 1 and 3b expression in Huh-7 cells expressing HCV core protein of different genotypes. Dig Dis Sci. 2012; 57:1598-1603.
44. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin, II, et al. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics. 2003; 19:524-531.
45. Sedwards S and Mazza T. Cyto-Sim: a formal language model and stochastic simulator of membrane-enclosed biochemical processes. Bioinformatics. 2007; 23:2800-2802.
46. Ballarini P, Guido R, Mazza T and Prandi D. Taming the complexity of biological pathways through parallel computing. Brief Bioinform. 2009; 10:278-288.
47. Rappa F, Greco A, Podrini C, Cappello F, Foti M, Bourgoin L, Peyrou M, Marino A, Scibetta N, Williams R, Mazzoccoli G, Federici M, Pazienza V and Vinciguerra M. Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma. PLoS One. 2013; 8:e54458.